Clinical experience with pentoxifylline in occlusive cerebrovascular disorders.
Pentoxifylline--3,7-dimethyl-1(5-oxo-hexyl) xanthine--a new vasodilator compound, was tried in 28 cases of occlusive cerebrovascular disease. A similar group of 24 patients were given xanthinol nicotinate. Although in terms of degree of improvement there was no significant difference in the two treatment groups, improvement was earlier in the group treated with pentoxifylline. No significant side effects were observed with any of the two drugs used in the present study.
D000328:Adult; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D005260:Female; D006429:Hemiplegia / Q000188:drug therapy; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy*; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D010431:Pentoxifylline / Q000008:administration & dosage / Q000627:therapeutic use*; D013064:Speech Disorders / Q000188:drug therapy; D013805:Theobromine / Q000031:analogs & derivatives*
D013805:Theobromine; D010431:Pentoxifylline